The first supply of COVID-19 vaccines is supplied via the global COVAX Facility. The COVAX facility has been set up to facilitate the equitable distribution of safe COVID-19 vaccines to all countries, as rapidly as possible.
Ministry of Health will be receiving COVID-19 vaccines in batches, with the first batch expected to arrive before end of JUNE 2021. Over the course of 2021, the Government expects to receive enough vaccines to vaccinate 20% of the population.
As there is limited global supply and high global demand for COVID-19 vaccines, Vanuatu’s vaccines will be prioritized and provided to those who are considered most vulnerable to COVID-19.
Vanuatu’s priority groups who will first receive the COVID-19 vaccine are health workers, front line workers (e.g. border workers, quarantine facility staff, public transport drivers), elderly (55 and above) and people over 35 with existing medical conditions.
Healthcare workers: Health workers continue to serve on the front line of the global fight against COVID-19 and have more risk to be exposed to be COVID-19 due to their occupation.
Other front-line workers: Such as airport workers, seaport- workers, quarantine facility staff, hoteliers working in quarantine facilities, disciplined forces and some other essential workers are prioritized as their jobs bring them into contact with people potentially exposed to COVID -19 and so they have a higher risk of exposure to the virus.
Older adults: Older adults are at significantly higher risk of developing severe illness or even death if they get COVID-19.
Individuals with existing health conditions: People with existing health conditions, like hypertension, diabetes, heart disease, are at significantly higher risk of developing severe illness or even death if they get COVID-19.
It is too early to know the duration of protection of COVID-19 vaccines. Research is ongoing to answer this question, at this stage we know that the vaccine provides at least 8 months protection against the virus.
This is why it is important that we all continue to follow the recommended public health safety measures, like covering our cough and sneeze, cleaning our hands regularly, wearing a mask, if recommended, and staying at home if feeling unwell.
There are strict measures in place to help ensure the safety of all COVID-19 vaccines.
Like all vaccines, COVID-19 vaccines need to go through rigorous tests and clinical trials, reviewed by independent expert committees before they can be used. Once a vaccine has been approved and is being rolled out in a country, it is very closely monitored to make sure that it remains safe for use and there are no adverse impacts experienced.
WHO and its partners are committed to speeding up the development of COVID-19 vaccines, whilst ensuring the highest standards of safety are kept.
In the past, vaccines were developed through a series of steps that took years. Now, because of the urgent need for COVID-19 vaccines, never seen before financial investments and scientific collaborations have helped fast-track their development.
Also, some steps in the research and development process have been happening in parallel which has helped speed up the process, while still maintaining strict clinical and safety standards. No shortcuts were taken and all safety checks were completed as required in any vaccine development and approvals process.
All viruses – including the virus that causes COVID-19 – evolve over time. When a virus replicates or makes copies of itself, it sometimes changes a little bit, which is normal for a virus. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus.
When a virus is spreading widely in a population and causing many infections, there is a higher chance the virus mutating increases. The more chances a virus has to spread, the more it replicates – and the more opportunities it has to undergo changes.
The COVID-19 vaccines that are currently in development or have been approved are expected to provide at least some protection against new virus variants because these vaccines trigger your body to develop a broad immune response. Therefore, changes or mutations in the virus should not make vaccines completely ineffective.
However, data on the new COVID-19 virus variants continues to be collected and analysed, including the effect of vaccination on these variants.
Need to continue other COVID-19 Preventative Measures
Yes. Vaccines will be an important tool in fighting COVID-19, but even the most effective vaccines will not end the pandemic on their own.
For instance, it is too early to know if COVID-19 vaccines will provide long-term protection against the virus. That's why we must continue using all the other tools and preventive practices for fighting COVID-19.
Individuals must continue taking steps to protect themselves and others. This includes hand washing, covering coughs and sneezes, physical distancing and staying at home if feeling unwell as well as following other public health recommendations.
Jenerol Infomesen long vaksin, vaksinesen mo Imunaesesen
Wetem limit saplae, hae diman mo nid blong COVID-19 Vaksin , bae vaksinesen program blong Vanuatu bae oli provaedem nomo long ol krup we oli kat hae Janis blong kasem COVID-19 Long Vanuatu, ol man we oli kat hae Janis blon gkasem sik COVID-19 hemi ol helt woka, frant laen woka (oslem ol man we oli wok long boda, ol staf blong ol kwarantin fasiliti, ol pablik transpot draeva), ol olfala (55 yia I ko antap) mo olgeta we oli gat sik long bodi blong olgeta we eij blong olgeta I stap bitwin 35 kasem 55 yia.
Vaksin blong COVID-19 i save protektem you long sik COVID-19. Taem you kasem vaksin bodi blong yu I save faet aekensem sik COVID-19. COVID-19 vaksin I save lowarem Janis blong man I kasem COVID-19 sik.
Olgeta we oli stap mekem risej oli stap wok naya blong faenem aot se stret vaksin I save protektem yu kasem wetaem. Naoia yumi save nomo se COVID-19 Vaksin I save protektem man blong samples 8 manis long sik COVID-19. So hemi impoten tumas blong yumi folem advaes blong Ministri blong Health, kavaremap maot taem yu kof o sniz, wasem hand oltaem, stap long haos sipos yu filim sik.
I kat strik rul I stap in ples blong mekem sua se sefti blong COVID-19 vaksin. Olsem efri vaksin, COVID- 19 vaksin I nid blong ko tru long fulap test mo klinikol trael, we I kat riviu wetem fulap indipenden ekspet komiti bifo oli save yusum. Taem oli akri wetem wan vaksin mo oli rolemaot long wan kaontri, oli stap monitarem blong mekem sua se hemi sef blong yumi usum mo I nogat impak blong hem.
Wol Helt Okonaesesen wetem ol patna blong hem oli komitim olgeta blong spidim ap ol divelopmen blong COVID-19 vaksin mo mekem sua se I kat hae standed blong sefti. Bifo ikam, ol vaksin oli divelopem mo I kat difren step we hemi tekem plenty yia. Tete from hemi impoten tumas blon gkat COVID-19 vaksin, bigfala mani oli spendem wetem kolaboresen blong ol saentis hemi helpem spidim divelopmen ia. Mo tu wetem sam step blong divelopmen long proses we I stap happen mo semtaem hemi helpem spidim proses mo mentenem strong klinikol mo sefti standed. I no kat sot kat we oli tekem mo ol sefti jek we oli komplitim olsem we hemi rikwae long divelopem blong vaskin mo pruvol proses.
Naoia I kat bigfala diman blong COVID-19 vaksin be ol kampani we prodiusum I smol. Blong naoia wetem limit saplae mo hae klobol blong COVID19 vaksin bambae oli praerotizem mo provaedem long olgeta we oli konsiderem se oli stap long risk o valnerebol long COVID-19.
Ifek blong Vaeres Variant (o jenjes) long COVID-19
Everi Vaeres- inkludim vaeres we I kosem COVID-19- I jenis folem taem. Hem ia I minim se taem wan vaeres hemi kopi hem wan, mo samtaem hemi save jenis smol, we hemi nomol blong wan vaeres. Olgeta jenis ia oli kolem mutesen. Wan vaeres wetem wan o tu (2) mutesen hemi rifea ‘ olsem wan ‘ variant’ long orijinol vaeras
Taem wan vaeras is spred ova long wan bigfala populasen mo kosem plante infeksen, i gat bigfala Janis se vaeras mutesen hemi inkris. Fasin olsem i givim Janis long vaeras blong i spred, mo tu hemi go hed blong ripliket o mekem kopi blong hem wan - olsem tu hemi i givim mo optuniti o Janis blong gat moa jenis
COVID-19 vaksin we oli bin divelopem o apruvum i gat expektesen blong provaedem sam proteksen akensem ol niu vaeras variant from nomo se ol vaksin ia oli save givim mesej i go long bodi blong yu blong divelopem wan jenerol imiun respon. Olsem jenjes o mutesen insaed long vaeras oli no save mekem vaksin blong ino ifektiv o no save wok gud. Nomata long hemia, ol data o infomesen blong niu COVID-19 vaeras variant oli kontiniu blong kolektem mo analaesem , tugeta wetem ol ifek blong vaksinesen long ol variant ia.
Nid blong kontiniu wetem ol narafala COVID-19 Priventiv Mesa
Yes, Vaksin bae hemi impoten tul blong faetem COVID-19, be bae ol gudfala o ifektiv vaksin bae oli no save endem pandemik ia olgeta nomo Exampol hemi eli iet blong save sipos COVID-19 vaksin bae hemi provaedem long –tem proteksen akensem vaeres. From risen ia nao yumi mas kontiniu blong yusum ol narafala tul mo priventiv praktis blong faetem COVID-19. Ol pipol oli mas kontiniu blong tekem step blong protektem olgeta mo ol narafala man. Mo hemi ia I minim se mas wasem han wetem sop mo wota oltaem, kaveremap nus mo maot taem yu kof o sniz, fisikel distens, mo stap long haus sipos yu no filim gud mo semtaem folem /aplaem ol narafala pablik helt rikomendesen.